{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:52:27Z","timestamp":1772754747575,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Polish Ministry of Science and Higher Education","award":["IP2012046072"],"award-info":[{"award-number":["IP2012046072"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.toxlet.2016.12.018","type":"journal-article","created":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T01:02:03Z","timestamp":1483491723000},"page":"59-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Role of CYP1A1 in the biological activity of methylated resveratrol analogue, 3,4,5,4\u2032-tetramethoxystilbene (DMU-212) in ovarian cancer A-2780 and non-cancerous HOSE cells"],"prefix":"10.1016","volume":"267","author":[{"given":"Hanna","family":"Piotrowska-Kempisty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Klupczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Trzybulska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Kulcenty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Sulej-Suchomska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Kuci\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Mikstacka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Wierzchowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Murias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanda","family":"Baer-Dubowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenon","family":"Kokot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadwiga","family":"Jodynis-Liebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxlet.2016.12.018_bib0005","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.2147\/IJN.S26237","article-title":"Preparation and characterization of realgar nanoparticles and their inhibitory effect on rat glioma cells","volume":"6","author":"An","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.toxlet.2016.12.018_bib0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1471-2407-9-187","article-title":"Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention","volume":"9","author":"Androutsopoulos","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.toxlet.2016.12.018_bib0015","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1016\/j.ejmech.2011.03.049","article-title":"Anticancer Effects of the metabolic products of the resveratrol analogue, DMU-212: structural requirements for potency","volume":"46","author":"Androutsopoulos","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.toxlet.2016.12.018_bib0020","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/exd.12721","article-title":"Activation of ERK1\/2 is required for the antimitotic activity of the resveratrol analogue 3,4,5,4\u2032-tetramethoxystilbene (DMU-212) in human melanoma cells","volume":"24","author":"Androutsopoulos","year":"2015","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.toxlet.2016.12.018_bib0025","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1016\/j.bmc.2007.05.046","article-title":"Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development","volume":"15","author":"Bruno","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.toxlet.2016.12.018_bib0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11886-016-0731-z","article-title":"Curing cancer, saving the heart: a challenge that cardioncology should not miss","volume":"18","author":"Cardinale","year":"2016","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.toxlet.2016.12.018_bib0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jsbmb.2014.11.003","article-title":"Cytochrome P450 1 family and cancers","volume":"147","author":"Go","year":"2015","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.toxlet.2016.12.018_bib0040","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/sj.bjc.6602300","article-title":"A methoxy derivative of resveratrol analogue selectively induced activation of the mitochondrial apoptotic pathway in transformed fibroblasts","volume":"92","author":"Gosslau","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.toxlet.2016.12.018_bib0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00280-008-0704-z","article-title":"Resveratrol analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol","volume":"63","author":"Ma","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.toxlet.2016.12.018_bib0050","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/1535-7163.363.3.3","article-title":"Cytochrome P450 enzymes: novel options for cancer therapeutics","volume":"3","author":"McFadyen","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.toxlet.2016.12.018_bib0055","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3846","article-title":"Aryl hydrocarbon receptor ligands in cancer: friend and foe","volume":"14","author":"Murray","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.toxlet.2016.12.018_bib0060","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.taap.2012.05.023","article-title":"Resveratrol analogue 3,4,4\u2032,5-tetramethoxystilbene inhibits growth, arrests cell cycle and induces apoptosis in ovarian SKOV-3 and A-2780 cancer cells","volume":"263","author":"Piotrowska","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.toxlet.2016.12.018_bib0065","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.tiv.2013.09.012","article-title":"Different susceptibility of colon cancer DLD-1 and LOVO cell lines to apoptosis induced by DMU-212, a synthetic resveratrol analogue","volume":"27","author":"Piotrowska","year":"2013","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.toxlet.2016.12.018_bib0070","doi-asserted-by":"crossref","first-page":"32627","DOI":"10.1038\/srep32627","article-title":"3\u2032-hydroxy-3,4,5,4\u2032-tetramethoxystilbene, the metabolite of resveratrol analogue DMU-212, inhibits ovarian cancer cell growth in vitro and in a mice xenograft model","volume":"6","author":"Piotrowska-Kempisty","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.toxlet.2016.12.018_bib0075","first-page":"A117","article-title":"DMU212: a novel CYP1B1 activated anticancer prodrug","volume":"86","author":"Potter","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.toxlet.2016.12.018_bib0080","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/sj.bjc.6600197","article-title":"The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1","volume":"86","author":"Potter","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.toxlet.2016.12.018_bib0085","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1021\/jm030785u","article-title":"Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents","volume":"46","author":"Roberti","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.toxlet.2016.12.018_bib0090","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.mrrev.2007.08.004","article-title":"Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad?","volume":"658","author":"Saiko","year":"2008","journal-title":"Mutat. Res."},{"key":"10.1016\/j.toxlet.2016.12.018_bib0095","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/sj.bjc.6601568","article-title":"Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4\u2032-tetramethoxystilbene","volume":"90","author":"Sale","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.toxlet.2016.12.018_bib0100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1053\/j.seminoncol.2016.02.018","article-title":"Cutaneous manifestations of nontargeted and targeted chemotherapies","volume":"43","author":"Shi","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.toxlet.2016.12.018_bib0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer Statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.toxlet.2016.12.018_bib0110","doi-asserted-by":"crossref","first-page":"17154","DOI":"10.3390\/molecules191117154","article-title":"Enhancing the Delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution?","volume":"19","author":"Smoliga","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.toxlet.2016.12.018_bib0115","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ygyno.2014.10.013","article-title":"Cancer-related and treatment-related fatigue","volume":"136","author":"Wang","year":"2015","journal-title":"Gynecol. Oncol."}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427416333677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427416333677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T14:40:37Z","timestamp":1658328037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427416333677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":23,"alternative-id":["S0378427416333677"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2016.12.018","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of CYP1A1 in the biological activity of methylated resveratrol analogue, 3,4,5,4\u2032-tetramethoxystilbene (DMU-212) in ovarian cancer A-2780 and non-cancerous HOSE cells","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2016.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}